- Details
- In this conversation, Fred Saad discusses the PEACE-3 trial results. The study compares enzalutamide plus radium-223 versus enzalutamide alone in metastatic castration-resistant prostate cancer patients with bone metastases. Dr. Saad discusses the trial's design, highlighting significant improvements in radiographic progression-free survival and overall survival with the combination therapy. They...
|
- Details
- Vincenza Conteduca discusses the RAPSON trial, which compares treatment sequencing of radium-223 and docetaxel in metastatic castration-resistant prostate cancer (mCRPC) patients who have progressed on androgen receptor pathway inhibitors. Dr. Conteduca discusses the trial design, which randomizes patients to receive either radium-223 followed by docetaxel or vice versa. The primary endpoint is ch...
|
- Details
- Oliver Sartor interviews Bertrand Tombal about the PEACE-3 trial. The study investigates the combination of radium-223 and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer. Dr. Tombal discusses the trial design, results, and implications. The study demonstrates significant improvements in radiographic progression-free survival an...
|
- Details
- Alicia Morgans interviews Neeraj Agarwal about his presentation on T-cell engaging treatments for prostate cancer. Dr. Agarwal discusses the rationale behind T-cell engagers, their potential to bypass the limitations of prostate cancer's cold tumor microenvironment, and the various tumor-associated antigens being targeted. He reviews several bispecific and trispecific T-cell engagers currently in...
|
- Details
- Oliver Sartor discusses the SPLASH trial results, evaluating Lutetium-177-PNT2002 in metastatic castration-resistant prostate cancer patients who progressed on ARPI therapy. The study shows significant improvement in radiographic progression-free survival for Lutetium-177-PNT2002 compared to alternate ARPI therapy, with a hazard ratio of 0.71. Dr. Sartor highlights the favorable safety profile and...
|
- Details
- Piet Ost discusses the STORM trial, a randomized study comparing stereotactic body radiotherapy (SBRT) with elective nodal radiotherapy (ENRT) in oligometastatic prostate cancer patients. The trial, involving 80% PSMA-PET scanned patients, includes six months of androgen deprivation therapy in both arms. Results show significant benefits for ENRT in biochemical recurrence-free survival and locoreg...
|
- Details
- Daniel Petrylak discusses a new approach to treating advanced prostate cancer using a PROTAC agent called ARV-766. Dr. Petrylak explains that PROTACs accelerate the body's natural protein disposal process, targeting the androgen receptor. The phase I/II study of ARV-766 shows promising results in patients with ligand-binding domain mutations, which occur in about 25% of cases. The drug demonstrate...
|
- Details
- Nonna Shakhnazaryan discusses a phase 1b dose escalation study of FOR46, a novel antibody-drug conjugate targeting CD46, in combination with enzalutamide for metastatic castration-resistant prostate cancer. The study establishes the maximally tolerated dose and shows promising results, with 71% of patients experiencing PSA declines, including some who previously progressed on enzalutamide. The med...
|
- Details
- Oliver Sartor discusses with Ravi Madan the implications of using PSMA PET scans in metastatic castration-resistant prostate cancer. Dr. Madan highlights concerns about prematurely changing treatments based on PSMA PET findings without established criteria for progression. He emphasizes the distinction between radiological progression and treatment failure, noting the lack of validated parameters...
|
- Details
- Andrea Miyahira discusses with Irene Casanova-Salas and Joaquin Mateo a Cancer Cell publication on using circulating tumor extracellular vesicles (EVs) to monitor metastatic prostate cancer evolution. The researchers describe their novel method for analyzing both DNA and RNA from EVs in patient plasma samples. They highlight the advantages of EV analysis over traditional ctDNA, including the abili...
|
